Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Sees Large Decrease in Short Interest

by · The Cerbat Gem

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI – Get Free Report) saw a significant decrease in short interest during the month of May. As of May 15th, there was short interest totaling 157,814 shares, a decrease of 75.4% from the April 30th total of 642,343 shares. Approximately 11.4% of the shares of the company are short sold. Based on an average daily volume of 156,698 shares, the days-to-cover ratio is presently 1.0 days.

Scinai Immunotherapeutics Stock Performance

Shares of NASDAQ SCNI traded up $0.00 during midday trading on Friday, hitting $0.45. 472,796 shares of the company’s stock were exchanged, compared to its average volume of 189,817. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.30 and a quick ratio of 1.30. The stock’s 50 day moving average price is $0.57 and its 200-day moving average price is $0.77. The firm has a market cap of $1.78 million, a P/E ratio of -0.05 and a beta of 2.19. Scinai Immunotherapeutics has a twelve month low of $0.41 and a twelve month high of $6.18.

Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) last issued its quarterly earnings data on Wednesday, April 1st. The company reported $3.80 earnings per share (EPS) for the quarter. The business had revenue of $0.27 million for the quarter.

Hedge Funds Weigh In On Scinai Immunotherapeutics

An institutional investor recently raised its position in Scinai Immunotherapeutics stock. Citadel Advisors LLC lifted its holdings in shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI – Free Report) by 146.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 28,630 shares of the company’s stock after buying an additional 17,031 shares during the period. Citadel Advisors LLC owned approximately 0.90% of Scinai Immunotherapeutics worth $36,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 58.41% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat, Scinai Immunotherapeutics presently has a consensus rating of “Sell”.

Check Out Our Latest Research Report on SCNI

Scinai Immunotherapeutics Company Profile

(Get Free Report)

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.

Read More